1655504-04-3

Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase with potential antineoplastic activity.

Orelabrutinib has been previously approved to treat  patients with relapsed or refractory (R/R) mantle cell lymphoma and R/R  chronic lymphocytic leukemia/small lymphocytic lymphoma.

Innobruka^TM

Class: non-receptor tyrosine kinase
Treatment: CLL, SLL, MCL
Elimination half-life = 4 h
Protein binding = not reported

Orelabrutinib (ICP-022) is a potent, orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).

Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR)  signaling pathway and BTK-mediated activation of downstream survival  pathways, inhibiting the growth of malignant B-cells that overexpress  BTK.